EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Monoclonal B‐Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect

Andrea Serafin, Emanuela Sant'Antonio, Fabrizio Mavilia, Francesca Gandini, Stefano De Pretis, Lydia Scarfò, Paolo Ghia

Hematological Oncology · 2025

DOI: 10.1002/hon.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2025. Verfasst von Andrea Serafin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Medicine, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Lymphocytosis, B-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal B‐cell lymphocytosis (MBL) is a hematologic condition defined by the presence of a small clonal B‐cell population in the peripheral blood, without clinical or laboratory evidence of lymphoproliferative disorders. It is classified into low‐count (LC‐MBL) and high‐count (HC‐MBL) subtypes based on clonal size. HC‐MBL shares genetic and biological features with early‐stage chronic lymphocytic leukemia (CLL), has a well‐established 1%–2% annual risk of progression, and is associated with an increased risk of infections, second malignancies and a reduced response to vaccines due to immune dysfunction. LC‐MBL, on the other hand, is a distinct entity with a lower likelihood of progression, but its potential impact on immune function remains unclear. While some studies suggest an association with increased infection risk and immune alterations, further research is needed to clarify its clinical significance. Beyond the risk of progression, MBL is increasingly recognized as a condition requiring careful management due to its broader implications on immune function and cancer susceptibility. Given these risks, preventive strategies are essential for all individuals with MBL, including adherence to cancer screening programs, vaccinations, smoking cessation, sun protection, and a healthy lifestyle to mitigate potential complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphocytosisB-LymphocytesHumansLeukemia, Lymphocytic, Chronic, B-Cell

Stichwörter der Autor:innen

CLLHC‐MBLLC‐MBLMBLclonal evolution

Autor:innen und Institutionen

  • Hematology Unit, Department of Medicine, University of Padova, Padova, Italy.
  • Strategic Research Program on CLL, IRCCS Ospedale San Raffaele, Milano, Italy.
  • IRCSS Ospedale San Raffaele, Milan, Italy.
  • Medical School, Università Vita-Salute San Raffaele, Milano, Italy.
  • Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Zitieren

APA

Serafin, A., Sant'Antonio, E., Mavilia, F., Gandini, F., De Pretis, S., Scarfò, L., & Ghia, P. (2025). Monoclonal B‐Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect. Hematological Oncology. https://doi.org/10.1002/hon.70084

Vancouver

Serafin A, Sant'Antonio E, Mavilia F, Gandini F, De Pretis S, Scarfò L, et al. Monoclonal B‐Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect. Hematological Oncology. 2025. doi:10.1002/hon.70084

BibTeX
@article{Serafin2025,
  author = {Serafin, Andrea and Sant'Antonio, Emanuela and Mavilia, Fabrizio and Gandini, Francesca and De Pretis, Stefano and Scarfò, Lydia and Ghia, Paolo},
  title = {Monoclonal B‐Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70084}
}
Kostenlos starten →